H-Index & Metrics Best Publications

H-Index & Metrics

Discipline name H-index Citations Publications World Ranking National Ranking
Biology and Biochemistry D-index 67 Citations 22,406 153 World Ranking 3535 National Ranking 1802

Overview

What is he best known for?

The fields of study he is best known for:

  • Enzyme
  • Gene
  • Cancer

The scientist’s investigation covers issues in Pharmacology, Monoclonal antibody, Drug, Antibody and Biochemistry. His biological study spans a wide range of topics, including Monomethyl auristatin E, Cytotoxic T cell and Potency. His studies in Monomethyl auristatin E integrate themes in fields like Cancer research and Cytotoxicity.

His Monoclonal antibody study incorporates themes from Cancer cell, Molecular biology, Affinity chromatography and In vitro. The Drug study combines topics in areas such as Pharmacokinetics, Drug delivery, Peptide and Monoclonal. His Antibody research includes themes of Gel electrophoresis and Antigen.

His most cited work include:

  • Development of potent monoclonal antibody auristatin conjugates for cancer therapy. (1022 citations)
  • Arming antibodies: prospects and challenges for immunoconjugates (977 citations)
  • Effects of Drug Loading on the Antitumor Activity of a Monoclonal Antibody Drug Conjugate (842 citations)

What are the main themes of his work throughout his whole career to date?

His scientific interests lie mostly in Biochemistry, Monoclonal antibody, Antibody, Pharmacology and Prodrug. His research in Monoclonal antibody intersects with topics in Molecular biology and Antigen. Peter D. Senter usually deals with Antibody and limits it to topics linked to Cancer research and Cancer and Cancer cell.

His Pharmacology research integrates issues from Monomethyl auristatin E, Antibody-drug conjugate and Potency. His Prodrug study combines topics from a wide range of disciplines, such as Stereochemistry and Alkaline phosphatase. His Drug research is multidisciplinary, relying on both Brentuximab vedotin and Drug delivery.

He most often published in these fields:

  • Biochemistry (29.11%)
  • Monoclonal antibody (27.05%)
  • Antibody (26.71%)

What were the highlights of his more recent work (between 2011-2021)?

  • Antibody (26.71%)
  • Biochemistry (29.11%)
  • Pharmacology (20.89%)

In recent papers he was focusing on the following fields of study:

His main research concerns Antibody, Biochemistry, Pharmacology, Drug and Cancer research. Monoclonal antibody is the focus of his Antibody research. His Monoclonal antibody study frequently intersects with other fields, such as Antigen.

His Biochemistry course of study focuses on Combinatorial chemistry and Tertiary amine, Amine gas treating and Maleimide. Peter D. Senter has included themes like Brentuximab vedotin, In vitro and Antibody-drug conjugate in his Pharmacology study. His research in Drug tackles topics such as Drug delivery which are related to areas like Stereochemistry.

Between 2011 and 2021, his most popular works were:

  • Antibody-Drug Conjugates in Cancer Therapy (481 citations)
  • The discovery and development of brentuximab vedotin for use in relapsed Hodgkin lymphoma and systemic anaplastic large cell lymphoma (472 citations)
  • SGN-CD33A: a novel CD33-targeting antibody–drug conjugate using a pyrrolobenzodiazepine dimer is active in models of drug-resistant AML (297 citations)

In his most recent research, the most cited papers focused on:

  • Enzyme
  • Gene
  • Cancer

His primary areas of study are Drug, Biochemistry, Antibody, Drug delivery and Pharmacology. Peter D. Senter has researched Drug in several fields, including Cancer, Pharmacokinetics and Brentuximab vedotin. His work deals with themes such as Monomethyl auristatin E, Anaplastic large-cell lymphoma, Lymphoma and Cancer research, which intersect with Pharmacokinetics.

His Biochemistry study frequently draws connections between related disciplines such as Combinatorial chemistry. Peter D. Senter mostly deals with Monoclonal antibody in his studies of Antibody. His Pharmacology research incorporates elements of Antileukemic agent and Antibody-drug conjugate.

This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.

Best Publications

Development of potent monoclonal antibody auristatin conjugates for cancer therapy.

Svetlana O Doronina;Brian E Toki;Michael Y Torgov;Brian A Mendelsohn.
Nature Biotechnology (2003)

1646 Citations

Effects of Drug Loading on the Antitumor Activity of a Monoclonal Antibody Drug Conjugate

Kevin J. Hamblett;Peter D. Senter;Dana F. Chace;Michael M. C. Sun.
Clinical Cancer Research (2004)

1335 Citations

Arming antibodies: prospects and challenges for immunoconjugates

Anna M Wu;Peter D Senter.
Nature Biotechnology (2005)

1300 Citations

cAC10-vcMMAE, an anti-CD30-monomethyl auristatin E conjugate with potent and selective antitumor activity.

Joseph A Francisco;Charles G Cerveny;Damon L Meyer;Bruce J Mixan.
Blood (2003)

1143 Citations

Monomethylvaline compounds capable of conjugation to ligands

Allen J Ebens;Brian E Toki;Mark X Sliwkowski;Paul Polakis.
(2004)

1100 Citations

Antibody–drug conjugates: targeted drug delivery for cancer

Stephen C Alley;Nicole M Okeley;Peter D Senter.
Current Opinion in Chemical Biology (2010)

817 Citations

Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells

Peter D. Senter;Mark G. Saulnier;Joseph P. Brown;David E. Kerr.
(1988)

747 Citations

The discovery and development of brentuximab vedotin for use in relapsed Hodgkin lymphoma and systemic anaplastic large cell lymphoma

Peter D Senter;Eric L Sievers.
Nature Biotechnology (2012)

737 Citations

Antibody-Drug Conjugates in Cancer Therapy

Eric L Sievers;Peter D Senter.
Annual Review of Medicine (2013)

736 Citations

Enhanced Activity of Monomethylauristatin F through Monoclonal Antibody Delivery: Effects of Linker Technology on Efficacy and Toxicity

Svetlana O. Doronina;Brian A. Mendelsohn;Tim D. Bovee;Charles G. Cerveny.
Bioconjugate Chemistry (2006)

670 Citations

If you think any of the details on this page are incorrect, let us know.

Contact us

Best Scientists Citing Peter D. Senter

Paul Polakis

Paul Polakis

Genentech

Publications: 67

Dario Neri

Dario Neri

École Polytechnique Fédérale de Lausanne

Publications: 64

Serge Muyldermans

Serge Muyldermans

Vrije Universiteit Brussel

Publications: 52

Richard Bucala

Richard Bucala

Yale University

Publications: 44

Gonçalo J. L. Bernardes

Gonçalo J. L. Bernardes

University of Cambridge

Publications: 42

Anna M. Wu

Anna M. Wu

City Of Hope National Medical Center

Publications: 37

Alain Beck

Alain Beck

University of Strasbourg

Publications: 36

David M. Goldenberg

David M. Goldenberg

Pennsylvania State University

Publications: 33

Mark S. Dennis

Mark S. Dennis

Genentech

Publications: 32

Lin Leng

Lin Leng

Yale University

Publications: 31

Stefan Magez

Stefan Magez

Ghent University

Publications: 31

Paul W. H. I. Parren

Paul W. H. I. Parren

Leiden University Medical Center

Publications: 30

Paul J. Carter

Paul J. Carter

Genentech

Publications: 29

Christoph Rader

Christoph Rader

Scripps Research Institute

Publications: 28

Andrew M. Scott

Andrew M. Scott

La Trobe University

Publications: 24

Chi-Huey Wong

Chi-Huey Wong

Scripps Research Institute

Publications: 24

Something went wrong. Please try again later.